시장보고서
상품코드
1793996

세계의 갑상선 기능 저하증 시장

Hypothyroidism

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 274 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 갑상선 기능 저하증 시장은 2030년까지 26억 달러에 도달

2024년에 18억 달러로 추정되는 세계의 갑상선 기능 저하증 시장은 2024-2030년에 CAGR 6.3%로 성장하며, 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 1차 갑상선 기능 저하증은 CAGR 7.1%를 기록하며, 분석 기간 종료시에는 16억 달러에 달할 것으로 예측됩니다. 2차 갑상선 기능 저하증 부문의 성장률은 분석 기간 중 CAGR 5.3%로 추정됩니다.

미국 시장은 4억 9,420만 달러, 중국은 CAGR 10.0%로 성장 예측

미국의 갑상선 기능 저하증시장은 2024년에 4억 9,420만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년 CAGR을 10.0%로, 2030년까지 5억 4,080만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.1%와 6.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계의 갑상선 기능 저하증시장 - 주요 동향과 촉진요인 정리

갑상선기능저하증이 공중보건 논의에서 전 세계의 주목을 받는 이유는 무엇인가?

갑상선 기능 저하증은 갑상선 호르몬 생산 부족을 특징으로 하는 질환으로, 전 세계에서 광범위하고 영향력 있는 건강 문제로 인식되고 있습니다. 갑상선은 그 크기가 작지만 신진대사, 성장, 에너지 균형 조절에 중요한 역할을 하는 기관입니다. 갑상선 기능이 저하되면 생리적 변화가 연쇄적으로 일어나 피로, 체중 증가, 우울증, 인지 장애, 추위에 대한 불내성 등을 유발하는 경우가 많습니다. 갑상선기능저하증은 일반적으로 고령화 사회와 연관되어 여성에게 많이 나타나지만, 인식의 향상, 진단 프로토콜의 개선, 생활습관 관련 스트레스 요인 등으로 인해 최근에는 젊은 층에서도 진단되는 경우가 많아지고 있습니다. 자가면역질환, 특히 하시모토 갑상선염 증가도 환자 수 증가에 크게 기여하고 있습니다. 일부 국가에서는 요오드 결핍, 특히 요오드 첨가 소금을 충분히 구할 수 없는 사람들에게 요오드 결핍이 여전히 심각한 원인으로 작용하고 있습니다. 전 세계 보건 당국과 내분비학 단체들은 특히 임산부, 노인, 갑상선 질환의 가족력이 있는 사람 등 고위험군에 대해 정기적인 검진을 통한 조기 발견의 필요성을 강조하고 있습니다. 북미와 아시아 일부 지역과 같이 전통적으로 유병률이 높은 지역뿐만 아니라 아프리카와 라틴아메리카의 일부 지역에서는 의료 인프라가 부족하여 과소 진단이 여전히 큰 문제로 대두되고 있습니다. 이 때문에 진단에 대한 접근성과 치료 가능성을 확대하기 위한 국제적인 공동연구에 박차를 가하고 있습니다. 또한 삶의 질, 정신건강, 만성질환 관리에 대한 전 세계의 관심은 보다 적극적인 의료 참여로 이어졌고, 갑상선 기능 저하증은 평생 관리와 임상적 관심이 필요한 우선순위 질환으로 각광받고 있습니다.

시장의 요구에 부응하기 위해 진단 및 치료 접근법은 어떻게 진화하고 있는가?

갑상선 기능 저하증 치료는 지난 10년간 크게 변화하여 거의 획일적인 치료 모델에서 보다 섬세하고 개별화된 접근 방식으로 전환되고 있습니다. 전통적인 표준 치료법으로는 티록신(T4)의 합성제인 레보티록신(Levothyroxine)을 오랫동안 투여해 왔으며, 대부분의 환자에서 호르몬 균형이 회복되고 있습니다. 하지만, 연구 결과 레보티록신 단독요법으로 최적의 증상 완화를 얻지 못하는 환자들이 존재한다는 사실이 밝혀졌습니다. 이 때문에 특히 갑상선자극호르몬(TSH) 수치가 정상화되었음에도 불구하고 피로감, 인지기능 저하, 기분장애를 계속 경험하는 환자에게는 T4와 트리요오드사이로닌(T3)을 모두 포함하는 병용요법에 대한 관심이 높아지고 있습니다. 진단 프로토콜도 더욱 정교해져 TSH 검사뿐만 아니라 유리 T4, T3, 갑상선 항체 수치도 측정할 수 있게 되어 갑상선 기능과 그 근본적인 원인을 보다 종합적으로 파악할 수 있게 되었습니다. 이와 함께 가정용 진단 키트의 기술 혁신으로 환자가 스스로 호르몬 수치를 모니터링할 수 있게 됨으로써 장기적인 치료 계획에 대한 참여와 순응도가 높아졌습니다. 제약업계는 생체이용률과 환자의 복약 순응도를 향상시킬 수 있는 액체 및 소프트젤 캡슐과 같은 새로운 갑상선 호르몬 보충제 제제로 대응하고 있습니다. 또한 디지털 헬스 플랫폼은 현재 증상 추적, 복약 알림, 내분비내과 전문의와의 원격 상담을 통해 갑상선 질환 관리를 지원하고 있습니다. 이러한 변화는 개인화된 치료, 편의성, 지속적인 모니터링을 중시하는 환자 중심의 치료 모델로 전환하는 것을 반영합니다. 그 결과, 진단과 치료 전략 모두 전 세계 갑상선 기능 저하증 환자들의 복잡하고 다양한 요구를 충족시키기 위해 진화하고 있습니다.

시장 역학에서 라이프스타일과 합병증의 역할은 무엇인가?

세계에서 갑상선기능저하증 증가는 종종 동반되거나 증상 진행에 기여하는 더 광범위한 생활습관 및 동반된 건강 문제와 분리해서 생각할 수 없습니다. 앉아서 생활하는 생활습관, 식습관 장애, 만성 스트레스, 비만 증가 등은 모두 갑상선 기능 장애를 유발하거나 악화시키는 요인입니다. 요오드, 셀레늄, 아연 등 필수 미량영양소가 부족한 식습관은 갑상선 호르몬의 합성과 전환에 직접적인 영향을 미칩니다. 영양의 다양성이 부족한 지역에서는 이러한 결핍이 일반적인 근본 원인입니다. 동시에, 1형 당뇨병, 류마티스 관절염, 체강내 자가면역질환은 갑상선기능저하증과 중복되는 경우가 많아 면역학적 취약성을 공유하고 있음을 시사하고 있습니다. 우울증이나 불안증과 같은 정신질환은 증상인 동시에 잠재적인 합병증이며, 종종 신체적, 정신적 건강 악화의 사슬을 유발하는 경우가 많습니다. 이러한 동반 질환의 교차점은 의료진이 갑상선 기능 저하증에 대처하는 방식을 변화시켜 내분비학적인 치료와 영양 상담, 정신건강 지원, 생활습관 개선을 결합한 보다 통합적인 접근법을 장려하고 있습니다. 일부 지역 공중보건 캠페인은 보다 광범위한 비감염성 질환(NCD) 전략에서 갑상선 건강을 강조하기 시작했으며, 조기 발견과 개입이 심혈관 질환, 불임, 심각한 대사이상과 같은 장기적인 합병증을 예방할 수 있다는 것을 인식하고 있습니다. 이러한 상호 연관된 요인의 복잡성은 약리학적인 개입과 함께 생활습관 관리에 맞춘 종합적인 치료 패키지, 건강 코칭 서비스, 모바일 애플리케이션의 개발에도 새로운 기회를 제공합니다. 이처럼 의학적, 행동학적, 사회적 변수의 융합은 현대인의 갑상선 기능저하증의 역학을 이해하고 대처하는 데 있으며, 핵심적인 주제가 되고 있습니다.

전 세계 갑상선 기능 저하증 시장의 성장을 가속하는 요인은 무엇인가?

갑상선 기능 저하증 시장의 성장은 의료 환경의 변화, 기술 발전, 환자 프로파일의 진화, 소비자 행동의 변화 등과 직접적으로 관련된 몇 가지 요인에 의해 주도되고 있습니다. 주요 요인은 전 세계에서 갑상선 질환의 유병률이 증가하고 있으며, 특히 호르몬 민감도가 증가하는 주요 계층인 고령화 인구와 여성들 사이에서 증가하고 있습니다. 특히 신흥 경제국의 의료 서비스 접근성 확대는 진단율 향상과 후속 치료 개선으로 이어져 잠재적 치료 기반을 확대하고 있습니다. 공중 보건 교육 및 소셜미디어를 통한 옹호 활동으로 갑상선 건강에 대한 인식이 높아지면서 증상이 악화되기 전이라도 조기에 검사하고 적극적으로 관리해야 한다는 인식이 확산되고 있습니다. 의약품 혁신도 중요한 역할을 하고 있으며, 각 제약사들은 증상 조절과 복약 순응도를 높이기 위해 서방형 제제 및 병용요법을 개발하고 있습니다. 신흥 시장에서 환자들은 개인화된 치료 옵션과 비침습적 모니터링 솔루션을 점점 더 많이 찾고 있으며, 이는 디지털 헬스 플랫폼과 원격 진단의 성장을 가속하고 있습니다. 또한 산전 관리와 산전 관리에서 갑상선 기능 검사의 통합은 특히 체계화된 산모 건강 프로그램이 있는 국가에서 일상적인 검사의 범위를 넓히고 있습니다. 의료 보험사 및 국가 의료 시스템은 다운스트림 합병증을 예방하기 위한 조기 갑상선 기능 저하증 관리의 비용 효율성을 인식하기 시작했으며, 이를 통해 상환 및 접근성을 지원하고 있습니다. 이러한 요인들은 새로운 치료 경로와 바이오마커 개선에 대한 지속적인 연구와 함께 진단, 의약품, 디지털 헬스 솔루션 등 다양한 분야에서 갑상선 기능 저하증 시장의 성장을 가속하고 있습니다. 헬스케어 생태계가 만성질환 관리를 최우선 과제로 삼고 있는 가운데, 갑상선기능저하증은 임상적, 상업적, 기술적으로 지속적인 투자의 초점으로 떠오르고 있습니다.

부문

질환 유형(1차 갑상선 기능 저하증, 2차 갑상선 기능 저하증, 기타 질환 유형), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예

  • Abbott Laboratories
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biophytis S.A.
  • Bio-Tech Pharmacal Inc.
  • Fresenius Kabi AG
  • Gedeon Richter Plc
  • GlaxoSmithKline plc(GSK)
  • Hikma Pharmaceuticals plc
  • IBSA Institut Biochimique SA
  • Lannett Company, Inc.
  • Merck KGaA
  • Mylan N.V.(part of Viatris Inc.)
  • Novartis AG
  • Pfizer Inc.
  • RLC Labs
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Westminster Pharmaceuticals, LLC

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴로 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Hypothyroidism Market to Reach US$2.6 Billion by 2030

The global market for Hypothyroidism estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Primary Hypothyroidism, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Secondary Hypothyroidism segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$494.2 Million While China is Forecast to Grow at 10.0% CAGR

The Hypothyroidism market in the U.S. is estimated at US$494.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$540.8 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Hypothyroidism Market - Key Trends & Drivers Summarized

Why Is Hypothyroidism Gaining Global Attention in Public Health Discussions?

Hypothyroidism, a condition characterized by insufficient thyroid hormone production, is increasingly being recognized as a widespread and impactful health issue across the globe. The thyroid gland, though small in size, plays a critical role in regulating metabolism, growth, and energy balance. When it underperforms, a cascade of physiological changes occurs, often leading to fatigue, weight gain, depression, cognitive impairment, and intolerance to cold. While commonly associated with aging populations and more prevalent in women, hypothyroidism is now being diagnosed in younger demographics due to increased awareness, better diagnostic protocols, and lifestyle-related stressors. The rise in autoimmune conditions, particularly Hashimoto’s thyroiditis, has also contributed significantly to growing case volumes. In several countries, iodine deficiency remains a critical contributing factor, especially in populations without adequate access to iodized salt. Global health authorities and endocrinology bodies are emphasizing the need for early detection through routine screening, particularly for at-risk groups including pregnant women, the elderly, and those with a family history of thyroid disorders. Beyond traditional regions of high prevalence such as North America and parts of Asia, underdiagnosis remains a significant issue in parts of Africa and Latin America due to inadequate healthcare infrastructure. This has spurred international collaborations aimed at expanding diagnostic access and treatment availability. The global focus on quality of life, mental health, and chronic disease management has also led to more proactive medical engagement, bringing hypothyroidism into the spotlight as a priority condition requiring lifelong care and clinical attention.

How Are Diagnosis and Treatment Approaches Evolving to Meet Market Demands?

The management of hypothyroidism has transitioned substantially over the past decade, moving from a largely uniform treatment model to more nuanced and personalized approaches. The traditional standard of care has long involved the administration of levothyroxine, a synthetic form of thyroxine (T4), which restores hormonal balance in most patients. However, research has revealed that a notable subset of patients does not achieve optimal symptom relief with levothyroxine monotherapy. This has led to growing interest in combination therapies that include both T4 and triiodothyronine (T3), especially in patients who continue to experience fatigue, cognitive slowdown, or mood disturbances despite normalized thyroid-stimulating hormone (TSH) levels. Diagnostic protocols have also become more sophisticated, incorporating not just TSH testing but also measurements of free T4, T3, and thyroid antibody levels, enabling a more comprehensive picture of thyroid function and underlying causes. In parallel, innovations in at-home diagnostic kits are allowing patients to self-monitor hormone levels, increasing engagement and compliance with long-term care plans. The pharmaceutical industry is responding with new formulations of thyroid hormone replacements, including liquid and soft-gel capsules, that improve bioavailability and patient adherence. Furthermore, digital health platforms are now supporting thyroid disease management through symptom tracking, medication reminders, and remote consultations with endocrinologists. These changes reflect a shift towards patient-centric care models that value individualized therapy, convenience, and continuous monitoring. As a result, both diagnosis and treatment strategies are evolving to meet the complex and varied needs of the global hypothyroidism population.

What Role Does Lifestyle and Comorbidity Play in Market Dynamics?

The rise of hypothyroidism globally cannot be examined in isolation from broader lifestyle patterns and comorbid health issues that often coexist or contribute to the condition’s progression. Sedentary lifestyles, poor dietary habits, chronic stress, and increasing rates of obesity are all contributing factors that can either trigger or exacerbate thyroid dysfunction. Diets lacking in essential micronutrients such as iodine, selenium, and zinc have a direct impact on thyroid hormone synthesis and conversion. In regions with poor nutritional diversity, these deficiencies are a common root cause. At the same time, autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, and celiac disease frequently overlap with hypothyroidism, suggesting a shared immunological vulnerability. Mental health conditions such as depression and anxiety are both symptoms and potential complications, often creating a cycle of worsening physical and emotional health. This intersection of comorbidities is reshaping how healthcare providers address hypothyroidism, prompting a more integrative approach that combines endocrinological care with nutritional counseling, mental health support, and lifestyle modification. Public health campaigns in some regions have begun emphasizing thyroid health in their broader non-communicable disease (NCD) strategies, recognizing that early detection and intervention can prevent long-term complications like cardiovascular disease, infertility, and severe metabolic disorders. The complexity of these interrelated factors also presents new opportunities for the development of holistic treatment packages, health coaching services, and mobile applications tailored to lifestyle management alongside pharmacological intervention. The convergence of medical, behavioral, and social variables is thus becoming a central theme in understanding and addressing the dynamics of hypothyroidism in modern populations.

What Factors Are Driving the Growth in the Hypothyroidism Market Globally?

The growth in the hypothyroidism market is driven by several factors that are directly tied to shifting healthcare landscapes, technological advancement, evolving patient profiles, and changes in consumer behavior. A major contributor is the increased global prevalence of thyroid disorders, particularly among aging populations and women, both of which represent key demographics with heightened hormonal sensitivity. Expanding access to healthcare services, especially in emerging economies, has led to higher diagnosis rates and improved follow-up care, thereby expanding the potential treatment base. Rising awareness around thyroid health, bolstered by public health education and social media advocacy, is encouraging individuals to seek early testing and proactive management, even before symptoms become debilitating. Pharmaceutical innovation is also playing a critical role, with companies developing extended-release formulations and combination therapies that aim to improve symptom control and adherence. In developed markets, patients are increasingly demanding personalized treatment options and non-invasive monitoring solutions, prompting growth in digital health platforms and remote diagnostics. Additionally, the integration of thyroid function screening in maternal and prenatal care is widening the scope of routine testing, particularly in countries with structured antenatal health programs. Health insurers and national healthcare systems are beginning to recognize the cost-effectiveness of early hypothyroidism management in preventing downstream complications, thereby supporting reimbursement and access. These factors, coupled with ongoing research into novel therapeutic pathways and improved biomarkers, are reinforcing the expansion of the hypothyroidism market across various segments including diagnostics, pharmaceuticals, and digital health solutions. As healthcare ecosystems continue to prioritize chronic disease management, hypothyroidism is emerging as a focal point of sustained clinical, commercial, and technological investment.

SCOPE OF STUDY:

The report analyzes the Hypothyroidism market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Primary Hypothyroidism, Secondary Hypothyroidism, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biophytis S.A.
  • Bio-Tech Pharmacal Inc.
  • Fresenius Kabi AG
  • Gedeon Richter Plc
  • GlaxoSmithKline plc (GSK)
  • Hikma Pharmaceuticals plc
  • IBSA Institut Biochimique SA
  • Lannett Company, Inc.
  • Merck KGaA
  • Mylan N.V. (part of Viatris Inc.)
  • Novartis AG
  • Pfizer Inc.
  • RLC Labs
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Westminster Pharmaceuticals, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hypothyroidism - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Thyroid Disorders Throws the Spotlight on Hypothyroidism as a Major Public Health Concern
    • Increased Screening and Early Diagnosis Propel Growth in Demand for Thyroid Hormone Replacement Therapies
    • Here's the Story: Aging Population and Hormonal Health Awareness Strengthen the Business Case for Long-Term Hypothyroidism Management
    • Advancements in TSH Testing and Diagnostic Tools Drive Early Detection and Personalized Treatment Approaches
    • Growing Preference for Synthetic and Bioidentical Hormones Expands the Therapeutic Landscape for Levothyroxine and Beyond
    • Here's How Digital Health Tools Are Enabling Medication Adherence and Remote Monitoring in Hypothyroid Patients
    • Rise in Autoimmune Conditions Like Hashimoto's Thyroiditis Fuels Incidence Rates Across Developed Markets
    • Consumer Demand for Clean-Label and Natural Supplements Spurs Growth in Alternative and Adjunctive Therapies
    • Increased Focus on Women's Health Drives Greater Awareness and Treatment Uptake in Female Patient Populations
    • Expansion of Telemedicine Platforms Supports Accessible Care and Prescription Management in Chronic Endocrine Disorders
    • Innovation in Slow-Release and Liquid Formulations Enhances Dosing Flexibility and Patient Compliance
    • Here's How Personalized Medicine and Genetic Testing Are Informing Next-Gen Thyroid Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hypothyroidism Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Primary Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Secondary Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hypothyroidism by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hypothyroidism by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hypothyroidism by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hypothyroidism by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Hypothyroidism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Hypothyroidism by Disease Type - Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Hypothyroidism by Disease Type - Percentage Breakdown of Value Sales for Primary Hypothyroidism, Secondary Hypothyroidism and Other Disease Types for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hypothyroidism by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hypothyroidism by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제